Core Viewpoint - The implementation of the first version of the commercial insurance innovative drug directory has begun, with significant implications for the use of innovative drugs in hospitals and outpatient settings, particularly under the "three exclusions" policy [1][3][7]. Group 1: Policy Implementation and Impact - The "three exclusions" policy allows innovative drugs included in the commercial insurance directory to be reimbursed separately from the bundled payment for hospital cases, which is seen as a major benefit for the inclusion of these drugs in hospitals [1][3]. - As of January 8, at least 28 provinces have issued notifications to implement the 2025 version of the national drug directory and the commercial insurance innovative drug directory, indicating a broad acceptance of these policies [3][4]. - The sales data from the National Medical Insurance Administration shows that from January 1 to 6, over 15 medical institutions recorded sales of commercial insurance innovative drugs, although most of these were completed before the directory was published [3][4]. Group 2: Challenges in Drug Utilization - There is uncertainty regarding the allocation of special case approvals for commercial insurance innovative drugs, as these approvals are limited to a small percentage of total cases, which may restrict access for patients [8][9]. - The outpatient use of commercial insurance innovative drugs remains largely unregulated, with no existing incentives or policies to support their prescription in outpatient settings [6][12]. - The lack of clear guidelines for the inclusion of commercial insurance innovative drugs in hospital formularies is hindering their adoption compared to nationally negotiated drugs [4][5]. Group 3: Market Dynamics and Future Directions - The market for commercial insurance innovative drugs is expected to grow, but many stakeholders remain cautious due to unresolved issues regarding prescription and payment processes [2][6]. - There is a call for clearer standards and collaboration among departments to ensure the effective use of commercial insurance innovative drugs without being subject to self-payment rate assessments [8][9]. - The potential for outpatient pharmacies to stock commercial insurance innovative drugs is being explored, with some regions already supporting this initiative, but concerns about the integration of outpatient prescriptions into hospital billing remain [11][12].

Core Insights - The commercial insurance innovative drug directory has been officially implemented since January 1, with the inclusion of drugs like Daratumumab β injection, but outpatient incentives for these drugs remain in a policy vacuum [1][2] - The "three exclusions" policy is seen as a significant but challenging measure to facilitate the entry of commercial insurance innovative drugs into hospitals [1][3] - There is a lack of clarity regarding the implementation details for the entry of commercial insurance innovative drugs into hospitals, which limits the ability of medical institutions to stock a wider variety of these drugs [4][5] Group 1 - The first version of the commercial insurance innovative drug directory was launched on January 1, and it includes specific drugs that can be reimbursed separately from the bundled payment system [1] - As of January 8, at least 28 provinces have mandated local medical institutions to hold pharmacy meetings by the end of February to discuss the integration of commercial insurance innovative drugs [2] - The "three exclusions" policy aims to allow innovative drugs to be used in hospitals without affecting the bundled payment system, but its practical implementation remains uncertain [3][7] Group 2 - The entry of commercial insurance innovative drugs into hospitals can either be through inclusion in special drug directories or by facilitating their hospital entry pathways [3] - Recent data shows that from January 1 to 6, over 15 medical institutions recorded sales of commercial insurance innovative drugs, although most of these were pre-configured before the directory's release [3][4] - The sales of commercial insurance innovative drugs are highly concentrated in a few products, particularly those used for Alzheimer's treatment [3] Group 3 - There are currently no specific assessment indicators for the hospital configuration of commercial insurance innovative drugs, unlike the established metrics for national negotiated drugs [4] - Some provinces have clarified that the use of national negotiated drugs will not be included in certain performance assessment metrics for public medical institutions, but it is unclear if this applies to commercial insurance innovative drugs [5] - The transition from hospital entry to patient medication involves prescription and payment processes, which currently face significant bottlenecks, especially in outpatient settings [6] Group 4 - The "three exclusions" policy is expected to be crucial for expanding the hospital sales of commercial insurance innovative drugs, but balancing interests among stakeholders is necessary for effective implementation [7] - A common approach to support the use of innovative drugs in hospitals is to open a "special case negotiation" green channel, but the limited application quota raises concerns about accessibility for commercial insurance innovative drugs [8] - The implementation of "exclusion payment" mechanisms is seen as a more definitive incentive for hospitals to use innovative drugs, but current policies primarily favor national negotiated drugs [9] Group 5 - The commercial insurance innovative drug directory's initial week saw sales primarily occurring in medical institutions, but the market potential remains limited due to the nature of the drugs included [11] - There is a push for retail pharmacies to stock commercial insurance innovative drugs, but concerns about prescription practices and reimbursement processes persist [12] - Future efforts should focus on aligning the commercial insurance innovative drug directory with the national insurance system to enhance confidence in the use of these drugs in hospitals [12]